Wai Lam W. Ling

Statistics

Publications

Citations

492

H-Index

Active since

2003

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

Wai Lam W. Ling is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in biotechnology, antibody characterization, and monoclonal antibodies.

Publications per year

2003–2021

Publications

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody

Yan Wang, Judith Hailey, Denise Williams et al. · Molecular Cancer Therapeutics · 2005 · 169 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Assessment of AMBR&lt;sup&gt;TM&lt;/sup&gt; as a model for high-throughput cell culture process development strategy

Sarath Moses, Matthew Manahan, Alexandre Ambrogelly et al. · Advances in Bioscience and Biotechnology · 2012 · 54 citations · Full text

Engineering, Bioengineering, Biotechnology +17

Case Study: An accelerated 8‐day monoclonal antibody production process based on high seeding densities

Ishai Padawer, Wai Lam W. Ling, Yunling Bai · Biotechnology Progress · 2013 · 52 citations

Pharmacy, Bioengineering, Biotechnology +15

Role of iron and sodium citrate in animal protein‐free CHO cell culture medium on cell growth and monoclonal antibody production

Yunling Bai, Changjian Wu, Jia Zhao et al. · Biotechnology Progress · 2010 · 50 citations

Pharmacy, Biochemistry, Immunology +17

Multi‐omics profiling of a CHO cell culture system unravels the effect of culture pH on cell growth, antibody titer, and product quality

Alison Lee, Yee Jiun Kok, Meiyappan Lakshmanan et al. · Biotechnology and Bioengineering · 2021 · 38 citations

Life Sciences, Biochemistry, Biotechnology +17

1–5 of 11